Skip to Content

Current landscape in the immuno-oncology treatment of non-melanoma skin cancers

Immunosuppression is a well-described risk factor for cutaneous squamous cell carcinoma (CSCC), and PD-L1 expression has been observed in advanced CSCC. In this Medtalk, Paolo Antonio Ascierte, MD, evaluates and describes the clinical experience with checkpoint inhibition and the current landscape in immuno-oncology treatment.

Paolo Antonio Ascierto

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top